It seems that the detection of KRAS mutations from blood still has limited value for the identification of early tumours or micrometastatic disease, which suggests that either a limited amount of ctDNA is released at these stages of the disease, or that the ctDNA concentration is so low and it is so degraded, that its detection requires more sensitive nucleic acid processing and analysis technologies. The gene discussed is KRAS; the disease is neoplasm.